MedTrace Logo

A Clinical Study of NLY01 in Patient's With Early Parkinson's Disease

NCT04154072 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 255

Last updated 2024-09-19

No results posted yet for this study

Summary

This is a phase 2 study designed to assess the safety, tolerability and efficacy of NLY01 in subjects with early untreated Parkinson's disease (PD). Evidence suggests NLY01, a pegylated form of exenatide, may be beneficial in PD and is being developed as a potential treatment for neurodegenerative disorders.

Conditions

  • Parkinson Disease

Interventions

DRUG

NLY01

exenatide and polyethylene glycol (PEG)

DRUG

Vehicle

Saline (Sodium Chloride)

Sponsors & Collaborators

  • Neuraly, Inc.

    lead INDUSTRY

Principal Investigators

  • Dan Lee · Neuraly, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-02-27
Primary Completion
2023-02-14
Completion
2023-02-14
FDA Drug
Yes

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04154072 on ClinicalTrials.gov